Trial Profile
A Randomized, Double-blind, Placebo and Active Treatment-Controlled Study in Psoriatic Patients to Assess the Tolerability, Pharmacokinetics and Efficacy of a Cream Formulation Containing 3% of P32/98.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2019
Price :
$35
*
At a glance
- Drugs Isoleucine thiazolidide (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Vivoryon Therapeutics
- 15 Jun 2011 New trial record